126 related articles for article (PubMed ID: 37096518)
1. [Correlation between
Gu ZY; Tao J; Cai YF; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):448-454. PubMed ID: 37096518
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and Influencing Factors of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Retrospective Analysis].
Zhang BL; Zhou J; Zhang GL; Gui RR; Lin QD; Zu YL; Yu FC; Zhao HF; Li Z; Wang J; Fu YW; Zhang LN; Zhou H; Fang BJ; Song YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1414-1419. PubMed ID: 30295260
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].
Wang Y; Liu YF; Tao Y; Jin SW; Mi JQ
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2868-2873. PubMed ID: 36153872
[No Abstract] [Full Text] [Related]
5. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
7. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
8. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
9. [The Prognostic Value of Early Relapse after Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma].
Tian WW; Ren RR; Zheng FL; Zhu QJ; Gong R; Wang T; Gao ZL; Ma LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):535-539. PubMed ID: 33812427
[TBL] [Abstract][Full Text] [Related]
10. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
Yang GZ; Wang GR; Wang HJ; Zhang YR; Wu Y; Li YC; Liu AJ; Leng Y; Gao W; Chen WM
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2345-2350. PubMed ID: 35970792
[No Abstract] [Full Text] [Related]
11. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
14. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
15. Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma.
Song GY; Jung SH; Kim K; Kim SJ; Yoon SE; Lee HS; Kim M; Ahn SY; Ahn JS; Yang DH; Kim HJ; Lee JJ
BMC Cancer; 2020 Aug; 20(1):803. PubMed ID: 32831058
[TBL] [Abstract][Full Text] [Related]
16. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
17. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
18. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
[No Abstract] [Full Text] [Related]
19. [Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone].
Xu JY; Yan WW; Fan HS; Liu JH; Du CX; Deng SH; Sui WW; Xu Y; Qiu LG; An G
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(30):2338-2344. PubMed ID: 35970791
[No Abstract] [Full Text] [Related]
20. [Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].
Gong YY; Yan XS; Wang YM; Pan JL; Zhai YY; Chen SN; Liu DD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):772-780. PubMed ID: 34105471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]